Teva Reaches License Deal With Prestige Biopharma for Cancer Medication in Europe

Dow Jones

2025/10/21

By Dean Seal

A subsidiary of Teva Pharmaceuticals Industries has reached a license agreement with Prestige Biopharma for the commercialization of the cancer medicine Tuznue across most European markets.

Teva Pharmaceuticals International said Monday that Prestige received marketing authorization last year from the European Commission for Tuznue, a biosimilar to Herceptin approved for the treatment of breast cancer and metastatic gastric cancer.

Under their license and supply deal, Teva has secured the rights to market and distribute Tuznue in a majority of European markets. Prestige will be responsible for production and supply.

"Teva's extensive market reach will drive the successful launch of Tuznue while accelerating the development of our broader biosimilar pipeline," Prestige CEO Lisa Park said.

Write to Dean Seal at dean.seal@wsj.com

(END) Dow Jones Newswires

October 20, 2025 16:48 ET (20:48 GMT)

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2577889599"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2577889599\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2577889599?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-21 04:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2577889599","market":"us","top_or_hot":-1,"title":"Teva Reaches License Deal With Prestige Biopharma for Cancer Medication in Europe","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Dean Seal \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  A subsidiary of <a href=\"https://laohu8.com/S/TEVA\">Teva</a> Pharmaceuticals Industries has reached a license agreement with Prestige Biopharma for the commercialization of the cancer medicine Tuznue across most European markets. \n</p>\n<p>\n  Teva Pharmaceuticals International said Monday that Prestige received marketing authorization last year from the European Commission for Tuznue, a biosimilar to Herceptin approved for the treatment of breast cancer and metastatic gastric cancer. \n</p>\n<p>\n  Under their license and supply deal, Teva has secured the rights to market and distribute Tuznue in a majority of European markets. Prestige will be responsible for production and supply. \n</p>\n<p>\n  \"Teva's extensive market reach will drive the successful launch of Tuznue while accelerating the development of our broader biosimilar pipeline,\" Prestige CEO Lisa Park said. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Dean Seal at dean.seal@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 20, 2025 16:48 ET (20:48 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Teva Reaches License Deal With Prestige Biopharma for Cancer Medication in Europe</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTeva Reaches License Deal With Prestige Biopharma for Cancer Medication in Europe\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2025-10-21 04:48</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Dean Seal \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  A subsidiary of <a href=\"https://laohu8.com/S/TEVA\">Teva</a> Pharmaceuticals Industries has reached a license agreement with Prestige Biopharma for the commercialization of the cancer medicine Tuznue across most European markets. \n</p>\n<p>\n  Teva Pharmaceuticals International said Monday that Prestige received marketing authorization last year from the European Commission for Tuznue, a biosimilar to Herceptin approved for the treatment of breast cancer and metastatic gastric cancer. \n</p>\n<p>\n  Under their license and supply deal, Teva has secured the rights to market and distribute Tuznue in a majority of European markets. Prestige will be responsible for production and supply. \n</p>\n<p>\n  \"Teva's extensive market reach will drive the successful launch of Tuznue while accelerating the development of our broader biosimilar pipeline,\" Prestige CEO Lisa Park said. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Dean Seal at dean.seal@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 20, 2025 16:48 ET (20:48 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4596","symbol_name":"哈里斯概念","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2577889599","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2577889599","pubTimestamp":1760993280,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"A subsidiary of Teva Pharmaceuticals Industries has reached a license agreement with Prestige Biopharma for the commercialization of the cancer medicine Tuznue across most European markets.Teva Pharmaceuticals International said Monday that Prestige received marketing authorization last year from the European Commission for Tuznue, a biosimilar to Herceptin approved for the treatment of breast cancer and metastatic gastric cancer.Under their license and supply deal, Teva has secured the rights to market and distribute Tuznue in a majority of European markets. Prestige will be responsible for production and supply.\"Teva's extensive market reach will drive the successful launch of Tuznue while accelerating the development of our broader biosimilar pipeline,\" Prestige CEO Lisa Park said.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4596":"哈里斯概念","BK4559":"巴菲特持仓","BK4584":"避孕概念","BK4007":"制药","BK4566":"资本集团","PBH":"普雷斯蒂奇","BK4588":"碎股","BK4585":"ETF&股票定投概念","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","TEVA":"梯瓦制药","BK4557":"大麻股"},"translate_title":"梯瓦与Prestige Biopharma在欧洲达成癌症药物许可协议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PBH":1.5,"TEVA":0.9},"content_text":"By Dean Seal \n\n\n \n\n\n  A subsidiary of Teva Pharmaceuticals Industries has reached a license agreement with Prestige Biopharma for the commercialization of the cancer medicine Tuznue across most European markets. \n\n\n  Teva Pharmaceuticals International said Monday that Prestige received marketing authorization last year from the European Commission for Tuznue, a biosimilar to Herceptin approved for the treatment of breast cancer and metastatic gastric cancer. \n\n\n  Under their license and supply deal, Teva has secured the rights to market and distribute Tuznue in a majority of European markets. Prestige will be responsible for production and supply. \n\n\n  \"Teva's extensive market reach will drive the successful launch of Tuznue while accelerating the development of our broader biosimilar pipeline,\" Prestige CEO Lisa Park said. \n\n\n \n\n\n  Write to Dean Seal at dean.seal@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 20, 2025 16:48 ET (20:48 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}